BRPI0608254A2 - anticorpos kim-1 para o tratamento de condições mediadas por th2 - Google Patents

anticorpos kim-1 para o tratamento de condições mediadas por th2

Info

Publication number
BRPI0608254A2
BRPI0608254A2 BRPI0608254-8A BRPI0608254A BRPI0608254A2 BR PI0608254 A2 BRPI0608254 A2 BR PI0608254A2 BR PI0608254 A BRPI0608254 A BR PI0608254A BR PI0608254 A2 BRPI0608254 A2 BR PI0608254A2
Authority
BR
Brazil
Prior art keywords
kim
antibodies
treatment
mediated conditions
mediated
Prior art date
Application number
BRPI0608254-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul D Rennert
Patricia Mccoon
Veronique Bailly
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0608254A2 publication Critical patent/BRPI0608254A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0608254-8A 2005-03-02 2006-03-02 anticorpos kim-1 para o tratamento de condições mediadas por th2 BRPI0608254A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65778905P 2005-03-02 2005-03-02
PCT/US2006/007441 WO2006094134A2 (en) 2005-03-02 2006-03-02 Kim-1 antibodies for treatment of th2-mediated conditions

Publications (1)

Publication Number Publication Date
BRPI0608254A2 true BRPI0608254A2 (pt) 2009-12-08

Family

ID=36648475

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608254-8A BRPI0608254A2 (pt) 2005-03-02 2006-03-02 anticorpos kim-1 para o tratamento de condições mediadas por th2

Country Status (14)

Country Link
US (2) US8206705B2 (cg-RX-API-DMAC10.html)
EP (2) EP1865985B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008531719A (cg-RX-API-DMAC10.html)
KR (1) KR101213894B1 (cg-RX-API-DMAC10.html)
CN (2) CN101166542A (cg-RX-API-DMAC10.html)
AT (1) ATE478707T1 (cg-RX-API-DMAC10.html)
AU (2) AU2006218489B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0608254A2 (cg-RX-API-DMAC10.html)
CA (1) CA2599967C (cg-RX-API-DMAC10.html)
DE (1) DE602006016413D1 (cg-RX-API-DMAC10.html)
IL (1) IL185653A (cg-RX-API-DMAC10.html)
NZ (1) NZ562045A (cg-RX-API-DMAC10.html)
WO (1) WO2006094134A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200708372B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064031A2 (en) * 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
MA43134A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes de transduction tumorale

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
JP2001503271A (ja) 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―１（ＭＡｄＣＡＭ―１）およびそのスプライス変異体
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP4094066B2 (ja) 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
KR100764256B1 (ko) 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
CN1160075C (zh) 1998-03-11 2004-08-04 卫福有限公司 杂环酰胺化合物在制备IgE抗体产生抑制剂中的用途
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
BRPI0509139A (pt) * 2004-03-24 2007-08-28 Telos Fharmaceuticals Inc composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
US8025557B2 (en) 2009-02-27 2011-09-27 Illinois Tool Works Inc. Sanding clay

Also Published As

Publication number Publication date
EP1865985A2 (en) 2007-12-19
AU2011202405B2 (en) 2013-03-28
AU2006218489B2 (en) 2011-02-24
DE602006016413D1 (de) 2010-10-07
US8206705B2 (en) 2012-06-26
US20130089539A1 (en) 2013-04-11
WO2006094134A3 (en) 2006-10-19
AU2011202405A1 (en) 2011-06-09
KR20070110411A (ko) 2007-11-16
NZ562045A (en) 2010-12-24
CA2599967A1 (en) 2006-09-08
AU2006218489A1 (en) 2006-09-08
WO2006094134A2 (en) 2006-09-08
KR101213894B1 (ko) 2012-12-20
HK1118007A1 (en) 2009-01-30
ZA200708372B (en) 2008-12-31
JP2012131825A (ja) 2012-07-12
EP2251037B1 (en) 2015-01-14
IL185653A (en) 2013-04-30
ATE478707T1 (de) 2010-09-15
JP2008531719A (ja) 2008-08-14
CN101166542A (zh) 2008-04-23
US20100150905A1 (en) 2010-06-17
CA2599967C (en) 2014-10-21
IL185653A0 (en) 2008-01-06
EP2251037A1 (en) 2010-11-17
EP1865985B1 (en) 2010-08-25
CN103751780A (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PT2987796T (pt) Boronoftalidas substituídas por halogéneo para o tratamento de infecções
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
EP1850658A4 (en) IMPROVED PROCESS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF RETINA
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
PT2444424T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
EP2046315A4 (en) THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
NL1028087A1 (nl) Sulfonamiderivaten voor de behandeling van ziekten.
PT1924139E (pt) Métodos e aparelhos para reduzir o teor de proteína de agentes de diluição de espermatozoides
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
BRPI0506723A (pt) métodos para o tratamento de distúrbios vasculares
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
ZA200708372B (en) KIM-1 antibodies for treatment of Th2-mediated conditions
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ES1057646Y (es) Protesis perfeccionada para el tratamiento quirurgico de las hernias de la ingle.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61P 11/06 (2006.01), A61P 3